How do I read and understand my Endometrial Cancer pathology report

Understanding Your Endometrial Cancer Pathology Report

Your pathology report is one of the most important documents in your cancer care. It describes what the pathologist found when examining your tissue under the microscope. Let me walk you through the key sections and what they mean.

MAIN SECTIONS OF YOUR REPORT

1. SPECIMEN INFORMATION

This describes what tissue was removed and examined.

What to look for:

• Type of surgery: Usually "Total Hysterectomy + Bilateral Salpingo-Oophorectomy" (TH/BSO), which means removal of the uterus, fallopian tubes, and ovaries
• Specimen integrity: Whether the tissue came out intact (good) or was fragmented/morcellated (which can affect staging)
• Tumor location: Where in the uterus the cancer was found

Why it matters: According to NCCN Guidelines, the way your specimen is handled affects how accurately your cancer can be staged and treated.

---

2. HISTOLOGIC TYPE (What kind of cancer cells)

This identifies the specific type of endometrial cancer.

Common types include:

• Endometrioid adenocarcinoma - Most common type, generally has better prognosis
• Serous carcinoma - More aggressive, requires closer monitoring
• Clear cell carcinoma - Also more aggressive
• Carcinosarcoma - Mixed cancer with both epithelial (glandular) and sarcoma (muscle-like) components

Why it matters: Different types are treated differently. Your oncologist will use this information to recommend specific therapies.

---

3. HISTOLOGIC GRADE (How abnormal the cells look)

Grades range from 1-3 (or sometimes G1-G3):

• Grade 1 (G1): Cells look most like normal endometrial cells (lower risk)
• Grade 2 (G2): Cells look somewhat abnormal (intermediate risk)
• Grade 3 (G3): Cells look very abnormal (higher risk)

Why it matters: Higher grades typically indicate more aggressive cancer and may influence whether you need additional treatment.

---

4. MYOMETRIAL INVASION (How deep the cancer penetrated)

This measures how far the cancer invaded into the myometrium (the muscle layer of the uterus).

What the report shows:

• Depth of invasion in millimeters (e.g., "invasion to 8mm")
• Myometrial thickness in millimeters (e.g., "of 12mm total thickness")
• Often expressed as a percentage: "invasion to 50% of myometrial thickness"

How to interpret:

• No invasion or <50%: Lower risk (Stage IA)
• ≥50% invasion: Higher risk (Stage IB)

Why it matters: Deeper invasion means cancer cells may have reached blood vessels or lymph vessels, which affects your stage and treatment decisions.

---

5. LYMPHOVASCULAR SPACE INVASION (LVSI)

This describes whether cancer cells were found in blood vessels or lymphatic vessels within the tumor.

What you'll see:

• Absent/No LVSI: Cancer cells were NOT found in vessels (better)
• Present/Substantial LVSI: Cancer cells WERE found in vessels (more concerning)

Why it matters: According to NCCN Guidelines, LVSI is an important risk factor that may influence whether you need additional treatment like radiation or chemotherapy.

---

6. CERVICAL STROMAL INVOLVEMENT

This indicates whether cancer spread into the cervix (the lower part of the uterus).

What you'll see:

• Absent: Cancer did not involve the cervix (Stage I)
• Present: Cancer extended into cervical tissue (Stage II)

Why it matters: Cervical involvement changes your stage and may affect treatment recommendations.

---

7. PERITONEAL/ASCITIC FLUID CYTOLOGY

This describes fluid that was collected from your abdomen during surgery and examined for cancer cells.

What you'll see:

• Negative/No malignant cells: No cancer cells found (better)
• Positive: Cancer cells were found in the fluid

Important note: According to NCCN Guidelines, while positive cytology doesn't change your official stage, it IS considered an adverse risk factor that your doctor will consider when planning treatment.

---

8. LYMPH NODE ASSESSMENT

This describes whether lymph nodes were removed and examined, and whether cancer was found in them.

What to look for:

• Number of lymph nodes examined (e.g., "12 pelvic lymph nodes")
• Sentinel lymph nodes (SLNs): Special nodes that drain the uterus, often examined with special techniques
• Lymph node status:
  • N0: No cancer in lymph nodes
  • N1: Cancer found in pelvic lymph nodes
  • N2: Cancer found in para-aortic (upper abdominal) lymph nodes

Why it matters: Lymph node involvement is crucial for staging and determines whether you need systemic therapy (chemotherapy).

---

9. MOLECULAR/GENETIC TESTING (The newer, important part)

According to NCCN Guidelines, your pathology report should include testing for four molecular subgroups. This is increasingly important for treatment decisions.

Tests you may see:

POLE Mutation Testing:

• POLE-mutated: Pathogenic mutation found (generally favorable prognosis, may allow treatment de-escalation)
• No POLE mutation: Standard approach applies

Mismatch Repair (MMR) Status or Microsatellite Instability (MSI):

• Normal/Proficient MMR or MSI-Low: Standard approach
• Deficient MMR (dMMR) or MSI-High (MSI-H): Indicates Lynch syndrome risk; may qualify for immunotherapy; genetic counseling recommended

p53 Immunohistochemistry (IHC):

• Normal/Wild-type pattern: Standard approach
• Aberrant/Mutant pattern: May indicate need for treatment intensification; HER2 testing recommended

HER2 Testing:

• Negative: Standard approach
• Positive/Overexpressed: May qualify for targeted therapy (trastuzumab)

Why it matters: According to NCCN Guidelines, these molecular subgroups "may respond to therapy differently and therefore may require escalation or de-escalation of therapy." This is cutting-edge personalized medicine.

---

PUTTING IT TOGETHER: YOUR STAGE

Your pathology findings combine to determine your FIGO stage:

• Stage IA: Cancer confined to uterus, <50% myometrial invasion
• Stage IB: Cancer confined to uterus, ≥50% myometrial invasion
• Stage II: Cancer invades cervical stroma but not beyond uterus
• Stage III: Cancer extends beyond uterus but confined to pelvis/abdomen
• Stage IV: Cancer extends beyond pelvis or involves bladder/bowel mucosa

---

QUESTIONS TO ASK YOUR ONCOLOGIST

Based on your pathology report, here are specific questions that will help you understand your situation:

1. "What is my FIGO stage, and what does that mean for my treatment?"

2. "What do my molecular test results (POLE, MMR/MSI, p53, HER2) show, and how will they influence my treatment plan?"

3. "Based on my myometrial invasion depth and LVSI status, do I need radiation therapy, chemotherapy, or both?"

4. "Do my results suggest I might be a candidate for any clinical trials?" (NCCN Guidelines strongly encourage clinical trial enrollment for patients with specific molecular profiles)

5. "Should I have genetic counseling given my pathology findings?" (Especially important if you have MMR deficiency or family history of cancer)

6. "What follow-up imaging or blood tests will you recommend, and how often?"

7. "Are there any biomarkers in my report that might make me eligible for targeted therapy or immunotherapy?"

---

IMPORTANT CONTEXT

Your pathology report is a detailed medical document, and it's completely normal if it feels overwhelming. The good news is that pathologists and oncologists use standardized language, so your report follows a